Resource Center
The Importance of Early Universal Screening to Identify Congenital CMV (cCMV)
The National CMV Foundation, Leading Physicians cCMV Testing Advocates, and Eurofins Viracor will help you learn more about congenital cytomegalovirus (cCMV) and how early testing with non-invasive sample types (like saliva) can lead to improved outcomes. This succinct and informative webinar will discuss the impact testing can make for neonates at risk, types of testing, and the advocacy work you can get involved with (not only in June, but year round). The great panel also answers viewer's questions after the main presentation.
Featured Resource
Immunity Testing: CMV in Lung Transplant Patients
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.
Search the Eurofins Viracor online test directory
for the most up-to-date assay offerings and information
Test Menu